Abstract
This review attempts to provide a broad overview of the changes in the cellular redox environment in breast cancer cells. The regulatory power of the redox environment lies in its capacity to control the growth behavior, spread, and differentiation. Neoplastic cells adapt to a wide variety of environmental conditions, including persistent oxidative stress and genomic instability by shifting their redox environment to more reductive conditions, which in its turn triggers upregulation of various redox sensitive prosurvival pathways. This review also examines the interactions between prosurvival signaling pathways, metallothioneins, and hydrogen peroxide generating dual oxidase, and presents a hypothesis to explain their relevance for therapeutic response.
Keywords: Breast cancer cells, intracellular redox state, redox signaling, drug resistance, metallothionein, superoxide dismutase, metal-responsive element, cysteine and glycine-rich protein 1, Lactate dehydrogenase, nitroblue-tetrazolium chloride, Glycogen synthase kinase 3
Current Cancer Drug Targets
Title: Redox Environment and its Meaning for Breast Cancer Cells Fate
Volume: 11 Issue: 4
Author(s): E. A. Ostrakhovitch
Affiliation:
Keywords: Breast cancer cells, intracellular redox state, redox signaling, drug resistance, metallothionein, superoxide dismutase, metal-responsive element, cysteine and glycine-rich protein 1, Lactate dehydrogenase, nitroblue-tetrazolium chloride, Glycogen synthase kinase 3
Abstract: This review attempts to provide a broad overview of the changes in the cellular redox environment in breast cancer cells. The regulatory power of the redox environment lies in its capacity to control the growth behavior, spread, and differentiation. Neoplastic cells adapt to a wide variety of environmental conditions, including persistent oxidative stress and genomic instability by shifting their redox environment to more reductive conditions, which in its turn triggers upregulation of various redox sensitive prosurvival pathways. This review also examines the interactions between prosurvival signaling pathways, metallothioneins, and hydrogen peroxide generating dual oxidase, and presents a hypothesis to explain their relevance for therapeutic response.
Export Options
About this article
Cite this article as:
A. Ostrakhovitch E., Redox Environment and its Meaning for Breast Cancer Cells Fate, Current Cancer Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/156800911795538129
DOI https://dx.doi.org/10.2174/156800911795538129 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
Current Neuropharmacology Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design The Use of Metabolising Systems for In Vitro Testing of Endocrine Disruptors
Current Drug Metabolism Medical Image Processing Technology for Diagnosing and Treating Cancers
Recent Patents on Biomedical Engineering (Discontinued) Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine Functions of S100 Proteins
Current Molecular Medicine Dual Antibacterial and Anticancer Activity of 4-Benzoyl-1-dichlorobenzoylthiosemicarbazide Derivatives
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Current Genomics Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology ERRATUM
Current Cancer Drug Targets Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine Circulating MicroRNAs and Blood-Brain-Barrier Function in Breast Cancer Metastasis
Current Pharmaceutical Design The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives
Current Topics in Medicinal Chemistry Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery